

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

NARAL abortion rights activists pose for a photo outside the U.S. Supreme Court in Washington, D.C. on April 14, 2023.
"This stay is the bare minimum," said one reproductive rights campaigner. "The imminent threat to access to mifepristone and abortion care remains."
"Mifepristone remains safe, effective, and AVAILABLE."
However, access to medication abortion remains at "severe risk." That was the message Friday from reproductive rights advocates after the United States Supreme Court temporarily blocked a ruling by a Texas federal judge that would effectively end access to abortion pills.
Justice Samuel Alitoissued a short order on the high court's "shadow docket" staying until next Wednesday last week's decision by U.S. 5th Circuit Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who ruled that the U.S. Food and Drug Administration's 2000 approval of mifepristone—one of two drugs typically used in tandem to induce abortion—was illegal.
Alito, who wrote the majority opinion in Dobbs v. Jackson Women's Health Organization—the ruling that canceled half a century of federal abortion rights—is assigned to the 5th U.S. Circuit Court of Appeals.
"While medication abortion remains accessible for now, this case should never have been heard in the first place," NARAL Pro-Choice America president Minni Timmaraju said in a statement. "Nothing about the rulings from the lower courts' Trump-appointed judges had any basis in medical science–both are steeped in reckless disinformation and total disregard for the law. As this case continues, safe and effective medication abortion in all 50 states is at severe risk."
Jenny Ma, senior counsel at the Center for Reproductive Rights, said Friday that "mifepristone will remain available as it has for the last 23 years, for at least five more days."
"This week has created whiplash for healthcare providers and patients—and this order provides cold comfort for a brief few days," Ma added. "But this case is far from over. The Supreme Court must take action next week to stop the chaos unleashed by these extreme decisions."
On Wednesday, a three-judge panel of the 5th Circuit Court temporarily blocked the part of Kacsmaryk's ruling that would have invalidated the FDA's approval of mifepristone. Nancy Northup, president and CEO of the Center for Reproductive Rights, called Wednesday's ruling "a wolf in sheep's clothing."
"The court rightly found that some claims were filed too late," Northup added, "but that should not distract from the radical assault on the FDA's decision-making authority and the fact that it will wreak havoc on the provision of medication abortion if it stands."
The full Supreme Court next week is expected to consider granting a longer stay of Kacsmaryk's decision.
According to the Center for Reproductive Rights, healthcare providers "have been thrown into chaos repeatedly this week, with the accessibility of mifepristone volleying between two federal district courts and a circuit court."
After Friday's stay, NARAL Pro-Choice America asserted:
The people hurt most by these bans and restrictions are those who already face barriers to accessing abortion care—including women; Black, Latina/x, Asian American, Native Hawaiian, Pacific Islander, and Indigenous people; those working to make ends meet; the LGBTQ+ community; immigrants; young people; those living in rural communities; people with disabilities, and other historically oppressed communities.
Rachel O'Leary Carmona, executive director at Women's March, said in a statement that "had the Supreme Court refused to act today, the restrictions imposed by the 5th Circuit would have taken effect across the nation. This stay is the bare minimum. The imminent threat to access to mifepristone and abortion care remains."
"Mifepristone has been safe and effective and proven that way for more than 20 years," O'Leary Carmona continued. "There is no doubt about the FDA's authority to regulate it, or that the drug helps save lives."
"This case should be a clarion call to defenders of democracy to take action," she asserted. "If we don't act now, our courts and democracy itself will be eroded beyond repair."
"That's why Women's March is turning out in D.C. and cities across the country this weekend," she added, referring to nationwide protests planned for Saturday. "Together, we can protect the right to safe, legal abortion care and ensure that everyone has the freedom to make decisions about their own bodies and lives."
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
"Mifepristone remains safe, effective, and AVAILABLE."
However, access to medication abortion remains at "severe risk." That was the message Friday from reproductive rights advocates after the United States Supreme Court temporarily blocked a ruling by a Texas federal judge that would effectively end access to abortion pills.
Justice Samuel Alitoissued a short order on the high court's "shadow docket" staying until next Wednesday last week's decision by U.S. 5th Circuit Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who ruled that the U.S. Food and Drug Administration's 2000 approval of mifepristone—one of two drugs typically used in tandem to induce abortion—was illegal.
Alito, who wrote the majority opinion in Dobbs v. Jackson Women's Health Organization—the ruling that canceled half a century of federal abortion rights—is assigned to the 5th U.S. Circuit Court of Appeals.
"While medication abortion remains accessible for now, this case should never have been heard in the first place," NARAL Pro-Choice America president Minni Timmaraju said in a statement. "Nothing about the rulings from the lower courts' Trump-appointed judges had any basis in medical science–both are steeped in reckless disinformation and total disregard for the law. As this case continues, safe and effective medication abortion in all 50 states is at severe risk."
Jenny Ma, senior counsel at the Center for Reproductive Rights, said Friday that "mifepristone will remain available as it has for the last 23 years, for at least five more days."
"This week has created whiplash for healthcare providers and patients—and this order provides cold comfort for a brief few days," Ma added. "But this case is far from over. The Supreme Court must take action next week to stop the chaos unleashed by these extreme decisions."
On Wednesday, a three-judge panel of the 5th Circuit Court temporarily blocked the part of Kacsmaryk's ruling that would have invalidated the FDA's approval of mifepristone. Nancy Northup, president and CEO of the Center for Reproductive Rights, called Wednesday's ruling "a wolf in sheep's clothing."
"The court rightly found that some claims were filed too late," Northup added, "but that should not distract from the radical assault on the FDA's decision-making authority and the fact that it will wreak havoc on the provision of medication abortion if it stands."
The full Supreme Court next week is expected to consider granting a longer stay of Kacsmaryk's decision.
According to the Center for Reproductive Rights, healthcare providers "have been thrown into chaos repeatedly this week, with the accessibility of mifepristone volleying between two federal district courts and a circuit court."
After Friday's stay, NARAL Pro-Choice America asserted:
The people hurt most by these bans and restrictions are those who already face barriers to accessing abortion care—including women; Black, Latina/x, Asian American, Native Hawaiian, Pacific Islander, and Indigenous people; those working to make ends meet; the LGBTQ+ community; immigrants; young people; those living in rural communities; people with disabilities, and other historically oppressed communities.
Rachel O'Leary Carmona, executive director at Women's March, said in a statement that "had the Supreme Court refused to act today, the restrictions imposed by the 5th Circuit would have taken effect across the nation. This stay is the bare minimum. The imminent threat to access to mifepristone and abortion care remains."
"Mifepristone has been safe and effective and proven that way for more than 20 years," O'Leary Carmona continued. "There is no doubt about the FDA's authority to regulate it, or that the drug helps save lives."
"This case should be a clarion call to defenders of democracy to take action," she asserted. "If we don't act now, our courts and democracy itself will be eroded beyond repair."
"That's why Women's March is turning out in D.C. and cities across the country this weekend," she added, referring to nationwide protests planned for Saturday. "Together, we can protect the right to safe, legal abortion care and ensure that everyone has the freedom to make decisions about their own bodies and lives."
"Mifepristone remains safe, effective, and AVAILABLE."
However, access to medication abortion remains at "severe risk." That was the message Friday from reproductive rights advocates after the United States Supreme Court temporarily blocked a ruling by a Texas federal judge that would effectively end access to abortion pills.
Justice Samuel Alitoissued a short order on the high court's "shadow docket" staying until next Wednesday last week's decision by U.S. 5th Circuit Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who ruled that the U.S. Food and Drug Administration's 2000 approval of mifepristone—one of two drugs typically used in tandem to induce abortion—was illegal.
Alito, who wrote the majority opinion in Dobbs v. Jackson Women's Health Organization—the ruling that canceled half a century of federal abortion rights—is assigned to the 5th U.S. Circuit Court of Appeals.
"While medication abortion remains accessible for now, this case should never have been heard in the first place," NARAL Pro-Choice America president Minni Timmaraju said in a statement. "Nothing about the rulings from the lower courts' Trump-appointed judges had any basis in medical science–both are steeped in reckless disinformation and total disregard for the law. As this case continues, safe and effective medication abortion in all 50 states is at severe risk."
Jenny Ma, senior counsel at the Center for Reproductive Rights, said Friday that "mifepristone will remain available as it has for the last 23 years, for at least five more days."
"This week has created whiplash for healthcare providers and patients—and this order provides cold comfort for a brief few days," Ma added. "But this case is far from over. The Supreme Court must take action next week to stop the chaos unleashed by these extreme decisions."
On Wednesday, a three-judge panel of the 5th Circuit Court temporarily blocked the part of Kacsmaryk's ruling that would have invalidated the FDA's approval of mifepristone. Nancy Northup, president and CEO of the Center for Reproductive Rights, called Wednesday's ruling "a wolf in sheep's clothing."
"The court rightly found that some claims were filed too late," Northup added, "but that should not distract from the radical assault on the FDA's decision-making authority and the fact that it will wreak havoc on the provision of medication abortion if it stands."
The full Supreme Court next week is expected to consider granting a longer stay of Kacsmaryk's decision.
According to the Center for Reproductive Rights, healthcare providers "have been thrown into chaos repeatedly this week, with the accessibility of mifepristone volleying between two federal district courts and a circuit court."
After Friday's stay, NARAL Pro-Choice America asserted:
The people hurt most by these bans and restrictions are those who already face barriers to accessing abortion care—including women; Black, Latina/x, Asian American, Native Hawaiian, Pacific Islander, and Indigenous people; those working to make ends meet; the LGBTQ+ community; immigrants; young people; those living in rural communities; people with disabilities, and other historically oppressed communities.
Rachel O'Leary Carmona, executive director at Women's March, said in a statement that "had the Supreme Court refused to act today, the restrictions imposed by the 5th Circuit would have taken effect across the nation. This stay is the bare minimum. The imminent threat to access to mifepristone and abortion care remains."
"Mifepristone has been safe and effective and proven that way for more than 20 years," O'Leary Carmona continued. "There is no doubt about the FDA's authority to regulate it, or that the drug helps save lives."
"This case should be a clarion call to defenders of democracy to take action," she asserted. "If we don't act now, our courts and democracy itself will be eroded beyond repair."
"That's why Women's March is turning out in D.C. and cities across the country this weekend," she added, referring to nationwide protests planned for Saturday. "Together, we can protect the right to safe, legal abortion care and ensure that everyone has the freedom to make decisions about their own bodies and lives."